Characterization of dopamine and α-adrenergic receptors in human prolactin-secreting adenomas with phj-dihydroergocryptine

John S. Ramsdell, Cynthia Bethea, Robert B. Jaffe, Charles B. Wilson, Richard I. Weiner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

One tenable hypothesis for the etiology of the development of prolactin-secreting adenomas is that a decrease in inhibitory dopaminergic regulation leads to increased lactotroph proliferation. Dopamine receptors have been repeatedly characterized on prolactin-secreting adenomas using labelled antagonists as ligands; however, no data are available on characterization of the receptor with a dopaminergic agonist. An agonist was utilized as the radioligand in the present study to permit the direct comparison of the pharmacological characteristics of the binding site with the biological response, the inhibition of prolactin secretion. This comparison has never been reported in tissues from the same species. Binding of the dopamine agonist and α-adrenergic antagonist [3H]-dihydroergocryptine ([3H]-DHE) to particulate fractions of surgically resected human prolactin-secreting adenomas was high affinity, monophasic, and saturable. Careful characterization of the [3H]-DHE binding by competitions with a large number of dopaminergic and α-adrenergic agents revealed the presence of both dopaminergic and α-adrenergic binding sites. The presence of a saturable, high affinity α-adrenergic binding site was confirmed with the specific α-adrenergic antagonist [3H]-WB4101 as a radioligand. Although the rank order of potency for dopaminergic compounds to compete for [3H]-DHE binding was consistent with an interaction with a dopamine receptor, the inhibitory constants (Ki) calculated from the competitions were higher than expected at an anterior pituitary dopamine receptor. This appeared to be due to the lower affinity of these agents at the α-adrenergic sites. The observed potency of dopaminergic compounds was inversely related to the number of α-adrenergic sites. The concentration of [3H]-DHE necessary to occupy half of the dopamine receptors (0.75 nM) on the particulate fractions was in close agreement with the amount of this compound which inhibits 50% of the suppressible prolactin secretion from cultured adenomas (0.35 nM). We conclude that prolactin-secreting adenomas contain a high affinity dopamine receptor which interacts with both agonists and antagonists in a similar fashion as reported for the anterior pituitary of several species. Atypically these tumors contain relatively large numbers of α-adrenergic sites which do not appear to be involved in the regulation of prolactin secretion.

Original languageEnglish (US)
Pages (from-to)518-525
Number of pages8
JournalNeuroendocrinology
Volume40
Issue number6
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Dihydroergocryptine
Dopamine Receptors
Prolactin
Adenoma
Adrenergic Receptors
Adrenergic Agents
Adrenergic Antagonists
Binding Sites
Dopamine Agonists
Lactotrophs
Dopamine Agents
Pharmacology
Ligands

Keywords

  • Dopamine
  • Dopamine receptors
  • Human adenoma
  • Prolactin
  • α-adrenergic receptors

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems
  • Neuroscience(all)

Cite this

Characterization of dopamine and α-adrenergic receptors in human prolactin-secreting adenomas with phj-dihydroergocryptine. / Ramsdell, John S.; Bethea, Cynthia; Jaffe, Robert B.; Wilson, Charles B.; Weiner, Richard I.

In: Neuroendocrinology, Vol. 40, No. 6, 1985, p. 518-525.

Research output: Contribution to journalArticle

Ramsdell, John S. ; Bethea, Cynthia ; Jaffe, Robert B. ; Wilson, Charles B. ; Weiner, Richard I. / Characterization of dopamine and α-adrenergic receptors in human prolactin-secreting adenomas with phj-dihydroergocryptine. In: Neuroendocrinology. 1985 ; Vol. 40, No. 6. pp. 518-525.
@article{47cac09f93624526a476ef99d0a698ad,
title = "Characterization of dopamine and α-adrenergic receptors in human prolactin-secreting adenomas with phj-dihydroergocryptine",
abstract = "One tenable hypothesis for the etiology of the development of prolactin-secreting adenomas is that a decrease in inhibitory dopaminergic regulation leads to increased lactotroph proliferation. Dopamine receptors have been repeatedly characterized on prolactin-secreting adenomas using labelled antagonists as ligands; however, no data are available on characterization of the receptor with a dopaminergic agonist. An agonist was utilized as the radioligand in the present study to permit the direct comparison of the pharmacological characteristics of the binding site with the biological response, the inhibition of prolactin secretion. This comparison has never been reported in tissues from the same species. Binding of the dopamine agonist and α-adrenergic antagonist [3H]-dihydroergocryptine ([3H]-DHE) to particulate fractions of surgically resected human prolactin-secreting adenomas was high affinity, monophasic, and saturable. Careful characterization of the [3H]-DHE binding by competitions with a large number of dopaminergic and α-adrenergic agents revealed the presence of both dopaminergic and α-adrenergic binding sites. The presence of a saturable, high affinity α-adrenergic binding site was confirmed with the specific α-adrenergic antagonist [3H]-WB4101 as a radioligand. Although the rank order of potency for dopaminergic compounds to compete for [3H]-DHE binding was consistent with an interaction with a dopamine receptor, the inhibitory constants (Ki) calculated from the competitions were higher than expected at an anterior pituitary dopamine receptor. This appeared to be due to the lower affinity of these agents at the α-adrenergic sites. The observed potency of dopaminergic compounds was inversely related to the number of α-adrenergic sites. The concentration of [3H]-DHE necessary to occupy half of the dopamine receptors (0.75 nM) on the particulate fractions was in close agreement with the amount of this compound which inhibits 50{\%} of the suppressible prolactin secretion from cultured adenomas (0.35 nM). We conclude that prolactin-secreting adenomas contain a high affinity dopamine receptor which interacts with both agonists and antagonists in a similar fashion as reported for the anterior pituitary of several species. Atypically these tumors contain relatively large numbers of α-adrenergic sites which do not appear to be involved in the regulation of prolactin secretion.",
keywords = "Dopamine, Dopamine receptors, Human adenoma, Prolactin, α-adrenergic receptors",
author = "Ramsdell, {John S.} and Cynthia Bethea and Jaffe, {Robert B.} and Wilson, {Charles B.} and Weiner, {Richard I.}",
year = "1985",
doi = "10.1159/000124124",
language = "English (US)",
volume = "40",
pages = "518--525",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Characterization of dopamine and α-adrenergic receptors in human prolactin-secreting adenomas with phj-dihydroergocryptine

AU - Ramsdell, John S.

AU - Bethea, Cynthia

AU - Jaffe, Robert B.

AU - Wilson, Charles B.

AU - Weiner, Richard I.

PY - 1985

Y1 - 1985

N2 - One tenable hypothesis for the etiology of the development of prolactin-secreting adenomas is that a decrease in inhibitory dopaminergic regulation leads to increased lactotroph proliferation. Dopamine receptors have been repeatedly characterized on prolactin-secreting adenomas using labelled antagonists as ligands; however, no data are available on characterization of the receptor with a dopaminergic agonist. An agonist was utilized as the radioligand in the present study to permit the direct comparison of the pharmacological characteristics of the binding site with the biological response, the inhibition of prolactin secretion. This comparison has never been reported in tissues from the same species. Binding of the dopamine agonist and α-adrenergic antagonist [3H]-dihydroergocryptine ([3H]-DHE) to particulate fractions of surgically resected human prolactin-secreting adenomas was high affinity, monophasic, and saturable. Careful characterization of the [3H]-DHE binding by competitions with a large number of dopaminergic and α-adrenergic agents revealed the presence of both dopaminergic and α-adrenergic binding sites. The presence of a saturable, high affinity α-adrenergic binding site was confirmed with the specific α-adrenergic antagonist [3H]-WB4101 as a radioligand. Although the rank order of potency for dopaminergic compounds to compete for [3H]-DHE binding was consistent with an interaction with a dopamine receptor, the inhibitory constants (Ki) calculated from the competitions were higher than expected at an anterior pituitary dopamine receptor. This appeared to be due to the lower affinity of these agents at the α-adrenergic sites. The observed potency of dopaminergic compounds was inversely related to the number of α-adrenergic sites. The concentration of [3H]-DHE necessary to occupy half of the dopamine receptors (0.75 nM) on the particulate fractions was in close agreement with the amount of this compound which inhibits 50% of the suppressible prolactin secretion from cultured adenomas (0.35 nM). We conclude that prolactin-secreting adenomas contain a high affinity dopamine receptor which interacts with both agonists and antagonists in a similar fashion as reported for the anterior pituitary of several species. Atypically these tumors contain relatively large numbers of α-adrenergic sites which do not appear to be involved in the regulation of prolactin secretion.

AB - One tenable hypothesis for the etiology of the development of prolactin-secreting adenomas is that a decrease in inhibitory dopaminergic regulation leads to increased lactotroph proliferation. Dopamine receptors have been repeatedly characterized on prolactin-secreting adenomas using labelled antagonists as ligands; however, no data are available on characterization of the receptor with a dopaminergic agonist. An agonist was utilized as the radioligand in the present study to permit the direct comparison of the pharmacological characteristics of the binding site with the biological response, the inhibition of prolactin secretion. This comparison has never been reported in tissues from the same species. Binding of the dopamine agonist and α-adrenergic antagonist [3H]-dihydroergocryptine ([3H]-DHE) to particulate fractions of surgically resected human prolactin-secreting adenomas was high affinity, monophasic, and saturable. Careful characterization of the [3H]-DHE binding by competitions with a large number of dopaminergic and α-adrenergic agents revealed the presence of both dopaminergic and α-adrenergic binding sites. The presence of a saturable, high affinity α-adrenergic binding site was confirmed with the specific α-adrenergic antagonist [3H]-WB4101 as a radioligand. Although the rank order of potency for dopaminergic compounds to compete for [3H]-DHE binding was consistent with an interaction with a dopamine receptor, the inhibitory constants (Ki) calculated from the competitions were higher than expected at an anterior pituitary dopamine receptor. This appeared to be due to the lower affinity of these agents at the α-adrenergic sites. The observed potency of dopaminergic compounds was inversely related to the number of α-adrenergic sites. The concentration of [3H]-DHE necessary to occupy half of the dopamine receptors (0.75 nM) on the particulate fractions was in close agreement with the amount of this compound which inhibits 50% of the suppressible prolactin secretion from cultured adenomas (0.35 nM). We conclude that prolactin-secreting adenomas contain a high affinity dopamine receptor which interacts with both agonists and antagonists in a similar fashion as reported for the anterior pituitary of several species. Atypically these tumors contain relatively large numbers of α-adrenergic sites which do not appear to be involved in the regulation of prolactin secretion.

KW - Dopamine

KW - Dopamine receptors

KW - Human adenoma

KW - Prolactin

KW - α-adrenergic receptors

UR - http://www.scopus.com/inward/record.url?scp=0021827669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021827669&partnerID=8YFLogxK

U2 - 10.1159/000124124

DO - 10.1159/000124124

M3 - Article

C2 - 2861582

AN - SCOPUS:0021827669

VL - 40

SP - 518

EP - 525

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 6

ER -